Targeting NaPi2b in ovarian cancer

•NaPi2b is expressed in malignant tissues with minimal expression in healthy tissues (85/85).•NaPi2b is a targetable biomarker with stable expression throughout disease course (72/85).•Archival tissue samples are sufficient to assess NaPi2b expression (68/85).•Robust diagnostic assays can be developed to reliably detect NaPi2b expression (80/85).•Early trials with NaPi2b antibody-drug conjugates in ovarian cancer are promising (83/85).